Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

918.05
-12.3000-1.32%
Post-market: 915.00-3.0500-0.33%16:27 EDT
Volume:3.43M
Turnover:3.14B
Market Cap:867.91B
PE:40.00
High:929.00
Open:925.00
Low:905.11
Close:930.35
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:1.25
T/O Rate:0.36%
Dividend:6.00
Dividend Rate:0.65%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:32.71
PE(LYR):40.00

Loading ...

Eli Lilly Stock (LLY) Rises on Plan to Invest $1 Billion in India

TIPRANKS
·
Feb 18

Lilly targets India as global export hub amid booming Mounjaro sales, executive says

Reuters
·
Feb 17

Eli Lilly Aims to Establish India as Global Export Hub Amid Mounjaro Sales Surge

Deep News
·
Feb 17

Is Eli Lilly (LLY) Pricing Make Sense After Tripling In Three Years?

Simply Wall St.
·
Feb 17

Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill

TIPRANKS
·
Feb 17

Eli Lilly to Join TD Cowen's 46th Annual Health Care Conference

Reuters
·
Feb 16

Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 16

REFILE-Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Reuters
·
Feb 16

Lilly's Retevmo Delivers Event-Free Survival Benefit As Adjuvant Therapy In Early-Stage Ret Fusion-Positive Lung Cancer

Reuters
·
Feb 16

Eli Lilly reports Phase 3 LIBRETTO-432 study of Retevmo met primary endpoint

TIPRANKS
·
Feb 16

Lilly Reports Positive Phase 3 Results for Selpercatinib in Early-Stage RET Fusion-Positive Lung Cancer

Reuters
·
Feb 16

Eli Lilly - Phase 3 Libretto-432 Study Meets Primary Endpoint With Improved Event-Free Survival

THOMSON REUTERS
·
Feb 16

Lilly's Retevmo (Selpercatinib) Delivers Substantial Event-Free Survival Benefit as an Adjuvant Therapy in Early-Stage Ret Fusion-Positive Lung Cancer

THOMSON REUTERS
·
Feb 16

Eli Lilly - Overall Survival Results Trended in Favor of Selpercatinib, but Were Immature at Time of This Analysis With Few Events Observed

THOMSON REUTERS
·
Feb 16

Soros Fund Management Llc Reports Share Stake of 22,334 Shares in Eli Lilly & Co - SEC Filing

THOMSON REUTERS
·
Feb 14

Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

TIPRANKS
·
Feb 14

Roche’s New Breast Cancer Trial Pits Its Pipeline Against Eli Lilly’s Standard: What It Means for RHHBY

TIPRANKS
·
Feb 14

Eli Lilly Prepares for Oral Weight-Loss Drug Market, Building Stockpiles Ahead of FDA Decision

Stock News
·
Feb 13

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 13

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Reuters
·
Feb 13